Cyfuse is involved in multifaceted ventures based on its proprietary platform technology, and is working on the development of next-generation technologies with a focus on novel regenerative medicine and other products. Our goal is to get cellular products from Japan out into the world, build a system for delivering cellular products in a rational format to patients the world over, and create “new treatment options” for all patients who are afflicted with illness or injury.

The current corporate ethos of Cyfuse can be summed up as “to contribute to dramatic progress in therapy through the practical application of innovative Bio 3D Printing technology.”

1. Development of regenerative medicine and other products, and development/sales of cellular products in the field of regenerative therapy
2. Contracting of cellular products for research and development/sales of novel organ models, for example, in the field of drug discovery support
3. We are involved in multifaceted ventures in the field of devices, such as the development/sales of the Bio 3D Printer and other devices, as well as the development of technical applications/novel techniques needed for the development of cellular products.